Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. Over 1,500 people from around the world attended MAPS’ Psychedelic Science 2013 conference in Oakland, CA. Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. DEA and the Controlled Substances Act.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 12, 2019

31) The United States DEA has stated that small amounts of other cannabinoids will also occur in all cannabis extracts, even those that purport to be CBD only – unless synthesized de novo, CBD isolate will always contain small amounts of THC when extracted from a plant. 2013 Sep;36(9):2530-5. 32: United States DEA.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

SpeedWeed

DECEMBER 28, 2018

It was fast tracked through the approval process in response to parents of severely epileptic children pushing for a way to legally use CBD, after seeing it work wonders for children profiled in a 2013 CNN documentary called Weed , hosted by Dr. Sanjay Gupta. Which Cannabis Strains Are Highest in CBD, According to Lab Data?

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40